Cepheid Gets FDA OK to Market Flu/RSV MDx Assay | GenomeWeb

NEW YORK (GenomeWeb) – Molecular diagnostics firm Cepheid today announced it has received clearance from the US Food and Drug Administration to market its Xpert Flu/RSV XC assay for determination of Flu A and Flu B and differentiation of respiratory syncytial virus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.